检索结果 - Albert Abad

  • Showing 1 - 15 results of 15
Refine Results
  1. 1
    Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer

    Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer 由 Eva Martínez-López, Albert Abad, Albert Font, Mariano Monzó, Isabel Ojanguren, Àlex Pifarré, José Javier Sánchez, Cristina Martîn, Rafael Rosell

    出版 1998
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines

    A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines 由 Eva Martinez‐Balibrea, Carmen Plasencia, Alba Ginés, Anna Martínez‐Cardús, Eva Musulén, Rodrigo Aguilera, José Luís Manzano, Nouri Neamati, Albert Abad

    出版 2009
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy

    Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy 由 Eva Martinez‐Balibrea, Anna Martínez‐Cardús, Eva Musulén, Alba Ginés, José Luís Manzano, Enrique Aranda, Carmen Plasencia, Nouri Neamati, Albert Abad

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Usefulness of Urinary Antigen Detection by an Immunochromatographic Test for Diagnosis of Pneumococcal Pneumonia in Children

    Usefulness of Urinary Antigen Detection by an Immunochromatographic Test for Diagnosis of Pneumococcal Pneumonia in Children 由 José Domínguez, S. Blanco, Carlos Rodrigo, M. Azuara, Núria Galí Espelt, A. Mainou, Albert Abad Esteve, A. Castellví, Cristina Prat, Lurdes Matas, V. Ausina

    出版 2003
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance

    Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance 由 Eva Martinez‐Balibrea, Anna Martínez‐Cardús, Alba Ginés, Vicenç Ruiz de Porras, Cátia Moutinho, Laura Layos, José Luís Manzano, Cristina Bugés, Sara Bystrup, Manel Esteller, Albert Abad

    出版 2015
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  6. 6
    UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

    UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy 由 Eva Martinez‐Balibrea, Albert Abad, Anna Martínez‐Cardús, Àngels Ginés, M. Valladares, M. Navarro, Enrique Aranda, E. Marcuello, Manuel Benavides, Bartomeu Massutí, Alfredo Carrato, Laura Layos, José Luís Manzano, Vı́ctor Moreno

    出版 2010
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway

    Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway 由 Vicenç Ruiz de Porras, Sara Bystrup, Anna Martínez‐Cardús, Raquel Pluvinet, Lauro Sumoy, Lynne Howells, Mark I. James, Chinenye Iwuji, José Luís Manzano, Laura Layos, Cristina Bugés, Albert Abad, Eva Martinez‐Balibrea

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer

    A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer 由 R. Rosell, José Gómez‐Codina, Carlos Camps, J Maestre, Jose Padille, Antonio Cantó, José Luís Mate, Shanrong Li, Jorge Roig, Ángel Olazábal, Mercedes Canela, Aurelio Ariza, Z Skácel, Jose Morera-Prat, Albert Abad

    出版 1994
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer

    Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer 由 Cátia Moutinho, Anna Martínez‐Cardús, Cristina Santos, Valentín Navarro-Perez, Eva Martinez‐Balibrea, Eva Musulén, F. Javier Carmona, Andrea Sartore‐Bianchi, Andrea Cassingena, Salvatore Siena, Elena Élez, Josep Tabernero, Ramón Salazar, Albert Abad, Manel Esteller

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

    Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines 由 D. Machover, Eduardo Díaz‐Rubio, Aimery de Gramont, A. Schilf, J Gastiaburu, S. Brienza, M. Itzhaki, G. Metzger, D. N'Daw, J. Vignoud, Albert Abad, Emmanuel Jean Francois, Érick Gamelin, M. Marty, Javier Sastre, Jean‐François Seitz, Marc Ychou

    出版 1996
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

    Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the... 由 Javier Sastre, M.L. Maestro, Auxiliadora Gómez‐España, Fernando Rivera, Manuel Valladares, Bartomeu Massutí, Manuel Benavides, Manuel Gallén, Eugenio Marcuello, Albert Abad, A. Arriví, Carlos Fernández-Martos, Encarnación González‐Flores, Josep Tabernero, Marta Vidaurreta, Enrique Aranda, Eduardo Díaz‐Rubio

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

    First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) 由 Alfredo Carrato, Albert Abad, Bartomeu Massutí, Cristina Grávalos, P. Escudero, Federico Longo-Muñoz, José-Luís Manzano, Auxiliadora Gómez, María José Safont, Javier Gállego, Beatriz García-Paredes, Carles Pericay, Rosario Dueñas, Fernando Rivera, Ferrán Losa, Manuel Valladares‐Ayerbes, Encarnación González‐Flores, Enrique Aranda

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

    A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic... 由 Helmut Frieß, Jan M. Langrehr, Helmut Oettle, Jochen Raedle, Marco Niedergethmann, Christian Dittrich, Dieter K. Hossfeld, Herbert Stöger, Bart Neyns, Peter Herzog, Pascal Piedbois, Frank Dobrowolski, Werner Scheithauer, Robert D. Hawkins, Frieder Katz, P Balcke, Jan B. Vermorken, Simon Van Belle, Neville Davidson, Albert Abad Esteve, Daniel Castellano, Jörg Kleeff, Adrien A. Tempia‐Caliera, Andreas Kovar, Johannes Nippgen

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

    First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III... 由 Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí, Javier Sastre, Albert Abad, Manuel Valladares, Fernando Rivera, María José Safont, Purificación Martínez de Prado, Manuel Gallén, Encarnación González‐Flores, Eugenio Marcuello, Manuel Benavides, Carlos Fernández-Martos, Ferrán Losa, P. Escudero, A. Arriví, Andrés Cervantes, Rosario Dueñas, Amelia López-Ladrón, Adelaida La Casta, Marta Llanos, Josep Tabernero, Antonio Antón, Enrique Aranda

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

    A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic... 由 Friess, Helmut, Langrehr, Jan M, Oettle, Helmut, Raedle, Jochen, Niedergethmann, Marco, Dittrich, Christian, Hossfeld, Dieter K, Stöger, Herbert, Neyns, Bart, Herzog, Peter, Piedbois, Pascal, Dobrowolski, Frank, Scheithauer, Werner, Hawkins, Robert, Katz, Frieder, Balcke, Peter, Vermorken, Jan, van Belle, Simon, Davidson, Neville, Esteve, Albert Abad, Castellano, Daniel, Kleeff, Jörg, Tempia-Caliera, Adrien A, Kovar, Andreas, Nippgen, Johannes

    出版 2006
    获取全文 获取全文 获取全文
    Text
    加到收藏夹
    Saved in:

检索工具: